Peer-Reviewed Publication
Mol Med2025;31(1):314.October 21, 2025Journal Article
SHIPi improves hematologic recovery after chemotherapy.
Sandra Fernandes1, Chiara Pedicone1, Otto M Dungan2, Angela Pacherille2, Shea T Meyer2, Shawn Dormann2, Carlos Del Fresno3, David Sancho4, Bonnie Toms1,5, Brian Walker1, Denzil Bernard6, John D Chisholm2, William G Kerr7,8,9,10
1Department of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY, USA.
2Department of Chemistry, Syracuse University, Syracuse, NY, USA.
3Immunomodulation Lab, Innate Immunity Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.
4Immunobiology Lab, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
5Department of Pediatrics, SUNY Upstate Medical University, Syracuse, NY, USA.
6, Atomwise, San Francisco, CA, USA.
7Department of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY, USA. wgkerr@mac.com.
8Immunobiology Lab, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain. wgkerr@mac.com.
9Department of Molecular Biology & Biochemistry, SUNY Upstate Medical University, Syracuse, NY, USA. wgkerr@mac.com.
10Department of Pediatrics, SUNY Upstate Medical University, Syracuse, NY, USA. wgkerr@mac.com.
Abstract
The use of recombinant growth factors has led to improved hematopoietic function after chemotherapy, but hematologic and immune complications still occur after chemotherapy which can be life-threatening. Here we show that pan-SHIPi compounds can induce endogenous G-CSF and TPO production in vivo and can also increase host survival after a lethal fungal challenge. In addition, we show that consiste…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans